Log In
BCIQ
Print this Print this
 

ESP-01 (formerly LY2880070)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionUndisclosed oral compound that inhibits cancer cell division or unchecked proliferation
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationSolid tumors
Indication DetailsTreat advanced or metastatic solid tumors
Regulatory Designation
PartnerEsperas Pharma Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today